Pharmacokinetics/Pharmacodynamics (PK/PD) of Cangrelor
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00102674|
Recruitment Status : Completed
First Posted : February 1, 2005
Last Update Posted : August 16, 2011
The purposes of this study are to:
- Evaluate the tolerability of two cangrelor regimens.
- Compare the PD of cangrelor regimens with oral clopidogrel.
|Condition or disease||Intervention/treatment||Phase|
|Healthy||Drug: cangrelor||Phase 1|
The purposes of this study are:
- To evaluate the tolerability of two cangrelor regimens of bolus plus infusion (A and B).
- To characterize the pharmacokinetics of Cangrelor (A and B).
- To compare the pharmacodynamics of cangrelor regimens with that of an oral 600 mg dose of clopidogrel (A, B, C and D).
- To determine the effect of prior cangrelor treatment on the pharmacodynamics of clopidogrel (C and D).
- To determine the effect of prior clopidogrel treatment on the pharmacodynamics of cangrelor (Group D).
- To determine the effects of concomitant clopidogrel and cangrelor exposure on the pharmacodynamics of clopidogrel (Group D).
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||40 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||The Pharmacokinetics and Pharmacodynamics of a Cangrelor Bolus Plus Infusion in Healthy Volunteers|
|Study Start Date :||March 2005|
|Study Completion Date :||May 2005|
- To evaluate the tolerability of two cangrelor regimens
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00102674
|United States, Kentucky|
|University of Kentucky|
|Lexington, Kentucky, United States, 40536|
|Principal Investigator:||Steven Steinhubl, MD||University of Kentucky|